Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

IPO Watch: WuXi PharmaTech Files For NYSE IPO

publication date: Jul 25, 2007
Company Seeks $715 Million Valuation -- As we reported earlier (see story), WuXi PharmaTech of Shanghai has been planning an IPO. The official confirmation is now in hand, as the company completed its initial IPO filing with the SEC. This gives the world a look at just how successful the biggest contract research organization (CRO) in China has been in its first six years of life. The company will list its new shares on the NYSE, where it will trade under the symbol WX. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital